# A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

> **NCT05366478** · PHASE1 · RECRUITING · sponsor: **Suzhou BlueHorse Therapeutics Co., Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Melanoma
- Non Small Cell Lung Cancer
- Cervical Carcinoma

## Interventions

- **DRUG:** Autologous tumor infiltrating lymphocytes (TILs)

## Key facts

- **NCT ID:** NCT05366478
- **Lead sponsor:** Suzhou BlueHorse Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-30
- **Primary completion:** 2024-05-30
- **Final completion:** 2029-05-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2022-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05366478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05366478, "A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05366478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*